Targeting bile‐acid signalling for metabolic diseases
Open accessThe DOI matches its Crossref record; 165 of the 169 references it cites were found in a registry or an index.
Abstract
Bile acids are increasingly being appreciated as complex metabolic integrators and signalling factors and not just as lipid solubilizers and simple regulators of bile-acid homeostasis. It is therefore not surprising that a number of bile-acid-activated signalling pathways have become attractive therapeutic targets for metabolic disorders. Here, we review how the signalling functions of bile acids can be exploited in the development of drugs for obesity, type 2 diabetes, hypertriglyceridaemia and atherosclerosis, as well as other associated chronic diseases such as non-alcoholic steatohepatitis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Through FXR activation, OCA modulates bile acid synthesis, absorption, transport, secretion, and metabolism, with a net effect of choleresis.(157,158)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [157]
In the citing paper
“In animal models, FXR activation has demonstrated antifibrotic and anti-inflammatory properties as well.(157)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [157]
In the citing paper
“After conjugation with either taurine or glycine, primary bile acids are released into the intestine to assist with lipid digestion and are recycled back into the liver (Thomas et al., 2008).”
From The Microbiota-Gut-Brain Axis (2019) · cites this paper as Thomas et al., 2008
In the citing paper
“By activating nuclear farnesoid X receptor (FXR) and plasma membrane TGR5 receptor, bile acids were shown to regulate systemic lipid, cholesterol, and glucose metabolism, as well as energy and immune homeostasis (Calmus and Poupon, 2014;de Aguiar Vallim et al., 2013;Thomas et al., 2008).”
From The Microbiota-Gut-Brain Axis (2019) · cites this paper as Thomas et al., 2008
In the citing paper
“In addition, FXR regulates other pathways with direct antiinflammatory and antifibrotic effects. 13-15”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [13]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220
Self-citationThe Enzymes, Regulation, and Genetics of Bile Acid Synthesis
Russell, D. W. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161712 · Cited by 2,069
Research works printed but not linked: 1
- Harnish, D. C. et al. A synthetic farnesoid X receptor (FXR) agonist protects against diet-induced dyslipidemia. J. Clin. Lipidol. 1, 362 (2007).
Cited by
Items 301–400 of 1,002
Mroz, M. S., Keating, N., Ward, J. B., Sarker, R., Amu, S., Aviello, G., Donowitz, M., Fallon, P. G., & Keely, S. J. (2014) · Gut · doi:10.1136/gutjnl-2013-305088 · Cited by 77
Hodge, R. J., Lin, J., Vasist Johnson, L. S., Gould, E. P., Bowers, G. D., Nunez, D. J., & on behalf of the SB‐756050 Project Team (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.34 · Cited by 75
Sonne, D. P., Hansen, M., & Knop, F. K. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0154 · Cited by 75
Diet1 Functions in the FGF15/19 Enterohepatic Signaling Axis to Modulate Bile Acid and Lipid Levels
Vergnes, L., Lee, J. M., Chin, R. G., Auwerx, J., & Reue, K. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.007 · Cited by 76
“…of several common clinical conditions, such as hypercholesterolemia, cardiovascular disease, bile acid malabsorption, gallstone disease, and type 2 diabetes (Angelin et al., 1999; Goldfine, 2008; Hageman et al., 2010; Khurana et al., 2011; Thomas et al., 2008; Walters and Pattni, 2010).”
Self-citationDiscovery of 3-Aryl-4-isoxazolecarboxamides as TGR5 Receptor Agonists
Evans, K. A., Budzik, B. W., Ross, S. A., Wisnoski, D. D., Jin, J., Rivero, R. A., Vimal, M., Szewczyk, G. R., Jayawickreme, C., Moncol, D. L., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901434t · Cited by 75
Interplay between cholesterol and drug metabolism
Režen, T., Rozman, D., Pascussi, J., & Monostory, K. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.05.014 · Cited by 90
Byun, S., Kim, D.-H., Ryerson, D., Kim, Y.-C., Sun, H., Kong, B., Yau, P., Guo, G., Xu, H. E., Kemper, B., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04697-5 · Cited by 75
Selenium Supplementation Alters Hepatic Energy and Fatty Acid Metabolism in Mice
Hu, X. Y., Chandler, J. D., Orr, M. L., Hao, L., Liu, K., Uppal, K., Go, Y., & Jones, D. P. (2018) · Journal of Nutrition · doi:10.1093/jn/nxy036 · Cited by 78
Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti‐tumor immunity
Sipe, L. M., Chaib, M., Pingili, A. K., Pierre, J. F., & Makowski, L. (2020) · Immunological Reviews · doi:10.1111/imr.12856 · Cited by 78
“29 Thus, the specific composition of circulating BA fundamentally provides regulation of important homeostatic systems.”
Oral delivery of taurocholic acid linked heparin–docetaxel conjugates for cancer therapy
Khatun, Z., Nurunnabi, M., Reeck, G. R., Cho, K.-J., & Lee, Y.-K. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.024 · Cited by 74
Cao, R., Cronk, Z. X., Zha, W., Sun, L., Wang, X., Fang, Y., Studer, E. J., Zhou, H., Pandak, W. M., Dent, P., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m004929 · Cited by 79
Mair, M., Zollner, G., Schneller, D., Musteanu, M., Fickert, P., Gumhold, J., Schuster, C., Fuchsbichler, A., Bilban, M., Tauber, S., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.049 · Cited by 75
Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases
Xu, Y. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00342 · Cited by 77
INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function
Comeglio, P., Cellai, I., Mello, T., Filippi, S., Maneschi, E., Corcetto, F., Corno, C., Sarchielli, E., Morelli, A., Rapizzi, E., et al. (2018) · Journal of Endocrinology · doi:10.1530/joe-17-0557 · Cited by 73
Advances in thermosensitive polymer-grafted platforms for biomedical applications
Le, P. N., Huynh, C. K., & Trân, N. Q. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.02.006 · Cited by 77
Hepatocellular carcinoma: Review of disease and tumor biomarkers
Kim, J. U., Shariff, M. I. F., Crossey, M. M. E., Gómez‐Romero, M., Holmes, E. C., Cox, I. J., Fye, H. K. S., Njie, R., & Taylor-Robinson, S. D. (2016) · World Journal of Hepatology · doi:10.4254/wjh.v8.i10.471 · Cited by 78
Hu, H., Zhang, S., Liu, F., Zhang, P., Muhammad, Z., & Pan, S. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b03731 · Cited by 72
Burrin, D. G., Ng, K., Stoll, B., & de Pipaón, M. S. (2014) · Advances in Nutrition · doi:10.3945/an.113.004796 · Cited by 78
“In addition to bile acid homeostasis, FGF19 exerts important regulatory effects on lipid, carbohydrate, and protein metabolism (74,75).”
BackgroundYamamoto, T., Harada-Shiba, M., Nakatani, M., Wada, S., Yasuhara, H., Narukawa, K., Sasaki, K., Shibata, M.-A., Torigoe, H., Yamaoka, T., et al. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.16 · Cited by 69
Sombetzki, M., Fuchs, C. D., Fickert, P., Österreicher, C. H., Mueller, M., Claudel, T., Loebermann, M., Engelmann, R., Langner, C., Sahin, E., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.020 · Cited by 69
A synthetic biology-based device prevents liver injury in mice
Bai, P., Ye, H., Xie, M., Saxena, P., Zulewski, H., Hamri, G. C., Djonov, V., & Fussenegger, M. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.03.020 · Cited by 79
“Because of the minor daily meal-based fluctuations and their excessive levels during liver-associated pathologies, SBAs have been suggested to play a more prominent metabolic role exceeding the one of emulsifying nutrients [2,11].”
BackgroundInfluentialDairy probiotics: Beyond the role of promoting gut and immune health
Ζουμποπούλου, Γ., Pot, B., Tsakalidou, E., & Papadimitriou, K. (2016) · International Dairy Journal · doi:10.1016/j.idairyj.2016.09.010 · Cited by 84
Zhang, Y., Guo, X. Q., Guo, J., He, Q., Li, H., Song, Y., & Zhang, H. (2014) · Scientific Reports · doi:10.1038/srep05654 · Cited by 70
Rath, C. M., Alexandrov, T., Higginbottom, S. K., Song, J., Milla, M. E., Fischbach, M. A., Sonnenburg, J. L., & Dorrestein, P. C. (2012) · Analytical Chemistry · doi:10.1021/ac302039u · Cited by 67
Metabolic Mechanisms in Obesity and Type 2 Diabetes: Insights from Bariatric/Metabolic Surgery
Cătoi, A. F., Pârvu, A., Mureşan, A., & Busetto, L. (2015) · Obesity Facts · doi:10.1159/000441259 · Cited by 68
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Roager, H. M., Stanton, C., & Hall, L. J. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2192151 · Cited by 75
FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS
Maneschi, E., Vignozzi, L., Morelli, A., Mello, T., Filippi, S., Cellai, I., Comeglio, P., Sarchielli, E., Calcagno, A., Mazzanti, B., et al. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0109 · Cited by 68
“During the past few years, bile acids (BAs) have emerged as important modulators of metabolic homeostasis and insulin resistance (Thomas et al. 2008).”
BackgroundPathak, P., Li, T., & Chiang, J. Y. L. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.485987 · Cited by 67
Dietary macronutrients and the aging liver sinusoidal endothelial cell
Cogger, V. C., Mohamad, M., Solon-Biet, S. M., Senior, A. M., Warren, A., O'Reilly, J. N., Tung, B. T., Svistounov, D., McMahon, A. C., Fraser, R., et al. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00949.2015 · Cited by 66
Bile acids at the cross-roads of gut microbiome–host cardiometabolic interactions
Ryan, P. M., Stanton, C., & Caplice, N. M. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0299-9 · Cited by 71
“In line with this, several bile acid receptor agonists/antagonists have been developed in recent years in an attempt to target this microbial–host crosstalk in certain metabolic pathologies [72].”
BackgroundMaczewsky, J., Kaiser, J., Gresch, A., Gerst, F., Düfer, M., Krippeit‐Drews, P., & Drews, G. (2018) · Diabetes · doi:10.2337/db18-0315 · Cited by 69
“exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor.”
BackgroundMethodMolecular Mechanisms of Autophagy in Cancer Development, Progression, and Therapy
Vitto, V. A. M., Bianchin, S., Zolondick, A. A., Pellielo, G., Rimessi, A., Chianese, D., Yang, H., Carbone, M., Pinton, P., Giorgi, C., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10071596 · Cited by 81
“FXR controls postprandial metabolic responses, and it is activated by elevated bile acid levels, an event correlated to repression of autophagy [71,72].”
BackgroundXiao, C., Wang, J., Su, C., Miao, Z., Tang, J., Ouyang, Y., Yan, Y., Jiang, Z., Fu, Y., Shuai, M., et al. (2022) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqac178 · Cited by 75
“Secondary bile acids can regulate host glucose and lipid metabolism by activating farnesoid X receptor and G-proteincoupled bile acid receptor 1 (39).”
BackgroundEmerging Concepts in the Pathophysiology of Type 2 Diabetes Mellitus
Surampudi, P. N., John‐Kalarickal, J., & Fonseca, V. A. (2009) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20113 · Cited by 91
Greuter, T., Malhi, H., Gores, G. J., & Shah, V. H. (2017) · JCI Insight · doi:10.1172/jci.insight.95354 · Cited by 67
Calorie restriction and its impact on gut microbial composition and global metabolism
Zheng, X., Wang, S., & Jia, W. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0670-8 · Cited by 65
Chevre, R., Trigueros‐Motos, L., Castaño, D., Chua, T., Corlianò, M., Patankar, J. V., Sng, L., Sim, L., Juin, T. L., Carissimo, G., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201701084rr · Cited by 65
“restricted as a result of either a lack of efficacy or adverse effects (23, 24).”
BackgroundAbnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma
Shen, R. D., Ke, L., Li, Q., Dang, X., Shen, S., Shen, J., Li, S., Liang, L., Peng, B., Kuang, M., et al. (2022) · Hepatology International · doi:10.1007/s12072-022-10299-7 · Cited by 71
Mao, Z., Gao, Z., Liu, D., Liu, Z., & Wu, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1124704 · Cited by 72
“BAs are synthesized from cholesterol in the hepatocytes and participates in the absorption of lipid as well as metabolic or inflammatory signaling pathways (40).”
BackgroundTransporter-Mediated Drug Delivery
Gyimesi, G., & Hediger, M. A. (2023) · Molecules · doi:10.3390/molecules28031151 · Cited by 77
“Most of the chemical species in bile are the primary bile acids cholic acid and chenodeoxycholic acid, which are conjugated with either glycine or taurine [157].”
BackgroundJAK-STAT signaling in hepatic fibrosis
Mair, M., Blaas, L., Österreicher, C. H., Casanova, E., & Eferl, R. (2011) · Frontiers in bioscience · doi:10.2741/3886 · Cited by 69
Baptissart, M., Vega, A., Martinot, E., Pommier, A. J., Houten, S. M., Marceau, G., de Haze, A., Baron, S., Schoonjans, K., Lobaccaro, J.-M. A., et al. (2014) · Hepatology · doi:10.1002/hep.27204 · Cited by 65
Self-citationHorvatits, T., Drolz, A., Roedl, K., Rutter, K., Ferlitsch, A., Fauler, G., Trauner, M., & Fuhrmann, V. (2016) · Liver International · doi:10.1111/liv.13201 · Cited by 74
Pellicciari, R., Passeri, D., Franco, F., Mostarda, S., Filipponi, P., Colliva, C., Gadaleta, R. M., Franco, P., Carotti, A., Macchiarulo, A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01126 · Cited by 72
Self-citationChetwynd, A. J., Zhang, W., Thorn, J. A., Lynch, I., & Ramautar, R. (2020) · Small · doi:10.1002/smll.202000295 · Cited by 66
Pierron, F., Normandeau, É., Defo, M. A., Campbell, P. G. C., Bernatchez, L., & Couture, P. (2011) · Ecotoxicology · doi:10.1007/s10646-011-0696-z · Cited by 68
Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?
Miras, A. D., & le Roux, C. W. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.205 · Cited by 64
Bile acid homeostasis paradigm and its connotation with cholestatic liver diseases
Yang, T., Khan, G. J., Wu, Z., Wang, X., Zhang, L., & Jiang, Z. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.007 · Cited by 65
Chattopadhyay, I., Gundamaraju, R., Jha, N. K., Gupta, P. K., Dey, A., Mandal, C. C., & Ford, B. M. (2022) · Disease Markers · doi:10.1155/2022/2941248 · Cited by 68
“SCFAs: Short-chain fatty acids HDAC: Histone deacetylases BAs: Bile acids LPS: Lipopolysaccharide CDCA: Chenodeoxycholic acid CA: Cholic acid DCA: Deoxycholic acid LCA: Lithocholic acid UDCA: Ursodeoxycholate TCDCA: Taurochenodeoxycholic acid CagA: Cytotoxin-associated gene A LAB: Lactic acid bacteria ROS: Reactive ox…”
BackgroundInfluentialEng, H. F., Niosi, M., McDonald, T. S., Wolford, A. C., Chen, Y., Simila, S. T. M., Bauman, J. N., Warmus, J. S., & Kalgutkar, A. S. S. (2010) · Xenobiotica · doi:10.3109/00498251003706598 · Cited by 64
“…et al. 2006), which represents a potentially useful therapeutic option for metabolic disorders such as type II diabetes and its associated complications (Evans et al. 2009; Fiorucci et al. 2009; Sato et al. 2008; Thomas et al. 2008; Arulmozhi & Portha 2006; Bojanowska 2005; Katsuma et al. 2005).”
BackgroundMicroRNAs in obesity-associated disorders
Abente, E. J., Subramanian, M., Ramachandran, V., & Najafi-Shoushtari, S. H. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.09.018 · Cited by 66
Design and strategies for bile acid mediated therapy and imaging
Nurunnabi, M., Khatun, Z., Revuri, V., Nafiujjaman, M., Cha, S., Cho, S., Huh, K. M., & Lee, Y.-K. (2016) · RSC Advances · doi:10.1039/c6ra10978k · Cited by 64
Flavonoids, gut microbiota, and host lipid metabolism
Zhou, M., Ma, J., Kang, M., Tang, W., Xia, S., Yin, J., & Yin, Y. (2023) · Engineering in Life Sciences · doi:10.1002/elsc.202300065 · Cited by 73
“It was shown that BAs mainly regulate glucose and lipid metabolism through FXR and TGR5 to modulate glycolipid metabolism [193].”
BackgroundKnop, F. K. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00137.2010 · Cited by 62
“Bile acid activation of TGR5 results in increased intracellular cAMP levels, which in brown adipose tissue and muscle cells modulates energy expenditure by activating type 2 iodothyronine deiodinase, which in turn deiodinates thyroxine to the active thyroid hormone triiodothyronine (43).”
BackgroundCummings, B. P., Bettaieb, A., Graham, J. L., Kim, J., Ma, F., Shibata, N. M., Stanhope, K. L., Giulivi, C., Hansen, F. B., Jelsing, J., et al. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.010421 · Cited by 72
“Furthermore, bile acid signaling through hepatic FXR decreases hepatic gluconeogenesis and lipogenesis (Thomas et al., 2008).”
Cai, F.-F., Wu, R., Song, Y.-N., Xiong, A., Chen, X.-L., Yang, M.-D., Yang, L., Yuanjia, H., Sun, M.-Y., & Su, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-33669-4 · Cited by 66
Bile acids and their effects on diabetes
Rajani, C., & Jia, W. P. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0644-x · Cited by 62
Drug-pathway association prediction: from experimental results to computational models
Wang, C.-C., Zhao, Y., & Chen, X. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa061 · Cited by 66
Diet‐derived microbial metabolites in health and disease
Roager, H. M., & Dragsted, L. O. (2019) · Nutrition Bulletin · doi:10.1111/nbu.12396 · Cited by 61
Fedorova, O. V., Zernetkina, V. I., Shilova, V. Y., Grigorova, Y. N., Juhász, O., Wei, W., Marshall, C. A., Lakatta, E. G., & Bagrov, A. Y. (2015) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.115.001217 · Cited by 63
Miyachi, T., Nagao, M., Shibata, C., Kitahara, Y., Tanaka, N., Watanabe, K., Tsuchiya, T., Motoi, F., Naitoh, T., & Unno, M. (2016) · Surgery · doi:10.1016/j.surg.2015.11.027 · Cited by 64
Metabolomics‐guided insights on bariatric surgery versus behavioral interventions for weight loss
Tulipani, S., Griffin, J., Palau‐Rodriguez, M., Cubillos, L. X. M., Bernal-López, M. R., Tinahones, F. J., Corkey, B. E., & Andrés‐Lacueva, C. (2016) · Obesity · doi:10.1002/oby.21686 · Cited by 66
Kojima, H., Yasuchika, K., Fukumitsu, K., Ishii, T., Ogiso, S., Miyauchi, Y., Yamaoka, R., Kawai, T., Katayama, H., Yoshitoshi-Uebayashi, E. Y., et al. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14666 · Cited by 61
Ogilvie, L. A., & Jones, B. V. (2012) · Gut · doi:10.1136/gutjnl-2012-302137 · Cited by 61
“Moreover, microbial transformation could also influence BA bioavailability for receptor binding.(2) In conjunction with the protective role of FXR activation described by Gadaleta and co-workers,(1) it is logical to hypothesise that the dysbiosis of the gut microbiota characteristic of IBD may alter capacity for BA mo…”
BackgroundMetabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson’s Disease
Graham, S. F., Rey, N. L., Ugur, Z., Yilmaz, A., Sherman, E., Maddens, M., Bahado-Singh, R. O., Becker, K., Schulz, E., Meyerdirk, L. K., et al. (2018) · Metabolites · doi:10.3390/metabo8040071 · Cited by 60
“Bile acids are molecules derived from cholesterol in hepatocytes and are used to emulsify fats in the small intestine and promote fat digestion and absorption [11,12].”
BackgroundGether, I. M., Nexøe-Larsen, C., & Knop, F. K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01008 · Cited by 56
Zhai, Q., Liu, Y., Wang, C., Zhao, J., Zhang, H., Tian, F., Lee, Y. K., & Chen, W. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b01004 · Cited by 63
Holtmann, T. M., Inzaugarat, M. E., Knorr, J., Geisler, L. J., Schulz, M., Bieghs, V., Frissen, M., Feldstein, A. E., Tacke, F., Trautwein, C., et al. (2021) · Cells · doi:10.3390/cells10102618 · Cited by 62
“BA are increasingly being considered as not just lipid solubilizers or cytotoxic detergents but as important signaling molecules; therefore, it is not surprising that recent focus was placed on BA-induced pathways as therapeutic targets in cholestatic liver disease [5].”
BackgroundInfluentialResearch Progress of Bile Acids in Cancer
Fu, J., Yu, M., Xu, W., & Yu, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.778258 · Cited by 67
“The degree of hydrophobicity of bile acid (the order of hydrophobicity is: LCA> DCA> CDCA> UDCA), which is highly correlated with the number and position of hydroxyl groups attached to it, is a fundamental determinant of its biological activity (13).”
BackgroundJiang, M., Li, F., Liu, Y., Gu, Z., Zhang, L., Lee, J., He, L., Vatsalya, V., Zhang, H., Deng, Z., et al. (2022) · Hepatology · doi:10.1002/hep.32608 · Cited by 64
“BAs can also act as signaling molecules through activation of several receptors, including farnesoid X receptor (FXR), Takada‐G‐protein receptor 5, and sphingosine‐ 1‐phosphate receptor 2.[2] FXR, highly expressed in the liver and intestine, is a BA‐sensing nuclear receptor that regulates many biological functions, in…”
BackgroundBurrin, D. G., Stoll, B., & Moore, D. D. (2013) · Journal of Animal Science · doi:10.2527/jas.2013-6331 · Cited by 68
“The second major bile acid receptor characterized in recent years is the G protein coupled membrane receptor (GPCR), TGR5, also known as G protein-coupled bile acid receptor 1 (GPBAR 1), or GPR131 (Kawamata et al., 2003; Thomas et al., 2008).”
BackgroundTranscriptional Regulation of CYP2D6 Expression
Pan, X., Ning, M., & Jeong, H. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.072249 · Cited by 71
“different stages of preclinical and clinical studies (Thomas et al., 2008).”
BackgroundChenodeoxycholic acid, an endogenous FXR ligand alters adipokines and reverses insulin resistance
Shihabudeen, M. S., Roy, D., James, J., & Thirumurugan, K. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.012 · Cited by 62
Fu, K., Ma, C., Wang, C., Zhou, H., Gong, L., Zhang, Y., & Li, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113185 · Cited by 61
Endogenous bile acid disposition in rat and human sandwich-cultured hepatocytes
Marion, T. L., Perry, C. H., St. Claire, R. L., & Brouwer, K. L. R. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.02.002 · Cited by 59
“The conversion of CDCA to MCA in rodents increases its hydrophilicity and further decreases the toxicity of CDCA (reviewed in Thomas et al. 2008).”
BackgroundPostprandial gut hormone responses and glucose metabolism in cholecystectomized patients
Sonne, D. P., Hare, K. J., Martens, P. C., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00435.2012 · Cited by 64
Impact of Pre-analytic Blood Sample Collection Factors on Metabolomics
Townsend, M. K., Bao, Y., Poole, E. M., Bertrand, K. A., Kraft, P., Wolpin, B. M., Clish, C. B., & Tworoger, S. S. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-1206 · Cited by 59
“This pattern likely reflects the intake of nutrients and reabsorption of bile acids from the intestine following ingestion of food (16).”
BackgroundCholesterol Transport Revisited: A New Turbo Mechanism to Drive Cholesterol Excretion
de Boer, J. F., Kuipers, F., & Groen, A. K. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.11.006 · Cited by 77
“This membrane domain harbors the phospholipid; bile salt; and sterol transporters ABCB4 (MDR2/3), ABCB11 (BSEP), and ABCG5/G8, which aid the secretion of phospholipids, bile acids, and sterols, respectively, into the bile [62,63].”
Analysis of metabolome changes in the bile acid pool in feces and plasma of antibiotic-treated rats
Behr, C., Slopianka, M., Haake, V., Strauss, V., Sperber, S., Kamp, H., Walk, T., Beekmann, K., Rietjens, I. M. C. M., & van Ravenzwaay, B. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.11.012 · Cited by 58
Yu, Y., Ding, Y., Wang, S., & Jiang, L. (2025) · Metabolites · doi:10.3390/metabo15060397 · Cited by 81
“Research suggests that FXR activation positively influences cholesterol, triglyceride, and glucose homeostasis [91].”
GSAASeqSP: A Toolset for Gene Set Association Analysis of RNA-Seq Data
Xiong, Q., Mukherjee, S., & Furey, T. S. (2014) · Scientific Reports · doi:10.1038/srep06347 · Cited by 60
Jang, J.-H., Rickenbacher, A., Humar, B., Weber, A., Raptis, D. A., Lehmann, K., Stieger, B., Moritz, W., Soll, C., Georgiev, P., et al. (2012) · Hepatology · doi:10.1002/hep.25626 · Cited by 58
Benigni, A., Perico, L., & Macconi, D. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6682 · Cited by 61
“Moreover, Sirt3 mRNA expression is downregulated in kidney biopsies from patients with obesity-related glomer-ulopathy and DN concomitant with a reduction in TGR5 (137), a G protein-coupled receptor that regulates glucose and lipid homeostasis (129).”
Alterations in Bile Acid Metabolism Associated With Inflammatory Bowel Disease
Li, N., Zhan, S., Tian, Z., Liu, C., Xie, Z., Zhang, S., Chen, M., Zeng, Z., & Zhuang, X. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa342 · Cited by 61
Bile acid transporter-mediated oral absorption of insulin via hydrophobic ion-pairing approach
Bashyal, S., Seo, J., Choi, Y. W., & Lee, S. K. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.060 · Cited by 58
Hepatocellular Carcinoma: How the Gut Microbiota Contributes to Pathogenesis, Diagnosis, and Therapy
Luo, W., Guo, S., Zhou, Y., Zhao, J., Wang, M., Sang, L.-X., Chang, B., & Wang, B. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.873160 · Cited by 65
“During the development of HCC, the accumulation of hydrophobic BAs, including CA, G-CA, CDCA, DCA, LCA, induce a variety of signals that prompt hepatocyte death (Thomas et al., 2008).”
BackgroundGe, X., Huang, S., Ren, C., & Zhao, L. (2023) · Molecules · doi:10.3390/molecules28052005 · Cited by 62
“Bile acids have established roles as signaling molecules in the metabolism and inflammation processes of obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease [30,36,37].”
BackgroundSynthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5
Herbert, M. R., Siegel, D. L., Staszewski, L. M., Cayanan, C. S., Banerjee, U., Dhamija, S., Anderson, J., Fan, A., Wang, L., Rix, P. J., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.08.014 · Cited by 61
Cystic Fibrosis Related Liver Disease—Another Black Box in Hepatology
Staufer, K., Halilbasic, E., Trauner, M., & Kazemi-Shirazi, L. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150813529 · Cited by 66
“its downstream targets (SHP, liver receptor homologue-1 (LRH-1), liver X receptor (LXR), sterol regulatory binding protein-1c (SREBP-1c)) are also involved in the regulation of hepatic lipogenesis and triglyceride metabolism [80].”
BackgroundResultTaguchi, K., Fukusaki, E., & Bamba, T. (2013) · Journal of Chromatography A · doi:10.1016/j.chroma.2013.05.043 · Cited by 62
Fu, S., Fan, J., Blanco, J., Gimenez-Cassina, A., Danial, N. N., Watkins, S. M., & Hotamisligil, G. S. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002902 · Cited by 57
“However further studies are warranted to explore the details of the mechanism and reconsider the potential of bile acid-based approaches for the treatment of diabetes and other metabolic diseases associated with obesity [50,51].”
BackgroundMa, X., Chi, Y.-H., Niu, M., Zhu, Y., Zhao, Y., Chen, Z., Wang, J., Zhang, C.-E., Li, J., Wang, L., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00014 · Cited by 57
Alkaloids of dendrobium nobile lindl. Altered hepatic lipid homeostasis via regulation of bile acids
Huang, S. Q., Wu, Q., Liu, H., Ling, H., He, Y., Wang, C., Wang, Z., Lu, Y., & Lu, Y. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.111976 · Cited by 60
Bile acids induce hepatic differentiation of mesenchymal stem cells
Sawitza, I., Kordes, C., Götze, S., Herebian, D., & Häussinger, D. (2015) · Scientific Reports · doi:10.1038/srep13320 · Cited by 56
Clinical application of transcriptional activators of bile salt transporters
Baghdasaryan, A., Chiba, P., & Trauner, M. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.12.001 · Cited by 60
Ge, H., Zhang, J., Gong, Y., Gupte, J., Ye, J., Weiszmann, J., Samayoa, K., Coberly, S., Gardner, J., Wang, H., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.592022 · Cited by 56
“Because FGFR4 KO mice had increased bile acid synthesis, the worsening effect on glucose metabolism appears inconsistent with effects of bile acids to prevent hyperglycaemia and insulin resistance (19) and the beneficial effects on glucose metabolism in other situations of increased bile acid synthesis, such as from b…”
BackgroundKeitel, V., & Häussinger, D. (2011) · Digestive Diseases · doi:10.1159/000324127 · Cited by 56
“The role of TGR5 in bile acid signaling is mainly elusive. However, recent data suggest that activation of TGR5 by bile acids may regulate glucose homeostasis [”
BackgroundBile Acids and GPBAR-1: Dynamic Interaction Involving Genes, Environment and Gut Microbiome
Portincasa, P., Ciaula, A. D., Garruti, G., Vacca, M., Angelis, M. D., & Wang, D. Q. ‐. (2020) · Nutrients · doi:10.3390/nu12123709 · Cited by 60
Shapiro, H., Suez, J., & Elinav, E. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12501 · Cited by 56
“profile and, indeed, bile acids have been used for the treatment of hypercholesterolemia.(67) Furthermore, and as described above, microbiota may modulate the”
BackgroundMethodInfluential
Metadata
- Authors
- Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K.
- Affiliations
- Institut de génétique et de biologie moléculaire et cellulaire (FR)
- University of Perugia (IT)
- Intercept Pharmaceuticals (United States) (US)
- Corresponding author
- Auwerx, Johan
- Schoonjans, Kristina
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-08
- Volume
- 7
- Issue
- 8
- Pages
- 678-693
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2078810890
- Cited by
- 1,422
- References
- 169
- Citations by year
- 2026: 81 · 2025: 92 · 2024: 106 · 2023: 107 · 2022: 113 · 2021: 90 · 2020: 83 · 2019: 82 · 2018: 78 · 2017: 81 · 2016: 75 · 2015: 75 · 2014: 71 · 2013: 77 · 2012: 47
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- European Commission
- Institut National de la Santé et de la Recherche Médicale
- Fondation pour la Recherche Médicale
- Ligue Contre le Cancer
- Centre National de la Recherche Scientifique
- Société Française de Nutrition
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Pharmacology (medical) › Berberine and alkaloids research
- Keywords
- bile acids, bile acid signaling, metabolic disorders, obesity, type 2 diabetes, hypertriglyceridemia, atherosclerosis, nonalcoholic steatohepatitis, therapeutic target, drug development
- MeSH terms
- Animals, Bile Acids and Salts, Humans, Metabolic Diseases, Signal Transduction, Drug Delivery Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.